Brunenders: A partially attenuated historic poliovirus type I vaccine strain

Journal of General Virology

Volumn 96, Issue 9, 2015, Pages 2614-2622

  Sanders, Barbara P ^a   Liu, Ying ^b   Brandjes, Alies ^a   van Hoek, Vladimir ^a   de los Rios Oakes, Isabel ^a   Lewis, John ^a,c   Wimmer, Eckard ^b   Custers, Jerome H H V ^a   Schuitemaker, Hanneke ^a   Cello, Jeronimo ^b   Edo Matas, Diana ^a  

^a Janssen Research and Development   (Netherlands)

^b STONY BROOK UNIVERSITY   (United States)

^c Aecsela Biologics Little Compton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; POLIOMYELITIS VACCINE; ORAL POLIOMYELITIS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BRUNENDERS; CONTROLLED STUDY; HUMAN POLIOVIRUS 1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIROGENESIS; VIRUS ATTENUATION; VIRUS CAPSID; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HISTORY; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; POLIOMYELITIS; POLIOMYELITIS VIRUS; SEQUENCE ALIGNMENT; SERODIAGNOSIS; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; HISTORY, 20TH CENTURY; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; SEQUENCE ALIGNMENT; VACCINES, ATTENUATED;

EID: 84941588093     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.000197     Document Type: Article

References (42)

1. Beale, J. A. (2011). The development of IPV. In History of Vaccine Development, pp. 179–187. Edited by S. A. Plotkin. New York: Springer.
2. Belnap, D. M., McDermott, B. M. Jr, Filman, D. J., Cheng, N., Trus, B. L., Zuccola, H. J., Racaniello, V. R., Hogle, J. M. & Steven, A. C. (2000). Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A 97, 73–78.
3. Bodian, D., Morgan, I. M. & Howe, H. A. (1949). Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types. Am J Hyg 49, 234–245.
4. Borzakian, S., Pelletier, I., Calvez, V. & Colbere-Garapin, F. (1993). Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells. J Virol 67, 2914–2917.
5. Böttiger, M. (1990). Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 8, 443–445.
6. Bouchard, M. J., Lam, D. H. & Racaniello, V. R. (1995). Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 69, 4972–4978.
7. Coid, C. R. & Beswick, T. S. (1960). Production of viraemia in cortisone-treated monkeys with the attenuated Brunenders strain of type-I poliovirus. Lancet 275, 414–415.
8. Coid, C. R., Tobin, J. O. & Beswick, T. S. (1960). The sensitivity of monkeys to subcutaneous inoculation of the Brunenders strain of type-I poliomyelitis virus. J Pathol Bacteriol 79, 325–330.
9. Coid, C. R., Beswick, T. S. & Tobin, J. O. (1961). The virulence of strains of poliovirus for cynomologus monkeys after subcutaneous injection. J Hyg (Lond) 59, 387–394.
10. Day, A. (2009). ‘An American tragedy’. The Cutter incident and its implications for the Salk polio vaccine in New Zealand 1955–1960. Health History 11, 42–61.
11. Enders, J. F., Weller, T. H. & Robbins, F. C. (1952). Alteration in pathogenicity for monkeys of Brunhilde strain of poliomyelitis virus following cultivation in human tissues. Fed Proc 11, 467.
12. Evans, D. G., Beswick, T. S. L., Coid, C. R., Ferguson, A. J., Perkins, F. T., Petts, A., Russell, K., Tobin, J. O’H & Yetts, R. (1957). Safety and antigenic potency testing of poliomyelitis vaccine; a report from the Biological Standards Control Laboratory, Medical Research Council Laboratories, London, N.W.3. Br Med J 2, 124–126.
13. Gear, J. (1956). The South African poliomyelitis vaccine. S Afr Med J 30, 587–594.
14. He, Y., Mueller, S., Chipman, P. R., Bator, C. M., Peng, X., Bowman, V. D., Mukhopadhyay, S., Wimmer, E., Kuhn, R. J. & Rossmann, M. G. (2003). Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol 77, 4827–4835.
15. Koike, S., Taya, C., Kurata, T., Abe, S., Ise, I., Yonekawa, H. & Nomoto, A. (1991). Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A 88, 951–955.
16. Macadam, A. J., Pollard, S. R., Ferguson, G., Skuce, R., Wood, D., Almond, J. W. & Minor, P. D. (1993). Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192, 18–26.
17. Martín, J. & Minor, P. D. (2002). Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 76, 5339–5349.
18. Martín, J., Crossland, G., Wood, D. J. & Minor, P. D. (2003). Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 84, 1781–1788.
19. Minor, P. D. (1986). Antigenic structure of poliovirus. Microbiol Sci 3, 141–144.
20. Minor, P. D., Ferguson, M., Evans, D. M., Almond, J. W. & Icenogle, J. P. (1986). Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67, 1283–1291.
21. Minor, P. D., Macadam, A. J., Stone, D. M. & Almond, J. W. (1993). Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21, 357–363.
22. Nathanson, N. & Langmuir, A. (1963). The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in theUnited Sates during the spring of 1955. III. Comparison of clinical character of vaccinated and contact cases occurring after use of high rate lots of Cutter Vaccine. Am J Hyg 78, 61–81.
23. Nicholson, R., Pelletier, J., Le, S. Y. & Sonenberg, N. (1991). Structural and functional analysis of the ribosome landing pad of poliovirus type 2: in vivo translation studies. J Virol 65, 5886–5894.
24. Offit, P. (2005). What went wrong at Cutter Laboratories. In The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis, pp. 105. New Haven, CT: Yale University Press.
25. Pliaka, V., Kyriakopoulou, Z. & Markoulatos, P. (2012). Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 11, 609–628.
26. Reed, L. J. & Muench, H. (1938). A simple method of estimating fifty per cent endpoint. Am J Hyg 27, 493–497.
27. Ren, R. B., Moss, E. G. & Racaniello, V. R. (1991). Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65, 1377–1382.
28. Rieder, E., Paul, A. V., Kim, D. W., van Boom, J. H. & Wimmer, E. (2000). Genetic and biochemical studies of poliovirus cis-acting replication element cre in relation to VPg uridylylation. J Virol 74, 10371–10380.
29. Sabin, A. B. (1955a). Behavior of chimpanzee avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci 230, 1–8.
30. Sabin, A. B. (1955b). Immunization of chimpanzees and human beings with avirulent strains of poliomyelitis virus. Ann N Y Acad Sci 61, 1050–1056.
31. Sabin, A. B. (1957). Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc 164, 1216–1223.
32. Sabin, A. B. & Boulger, L. R. (1973). History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1, 115–118.
33. Salk, J. E. (1953). Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 151, 1081–1098.
34. Sanders, B. P., Edo-Matas, D., Custers, J. H., Koldijk, M. H., Klaren, V., Turk, M., Luitjens, A., Bakker, W. A., Uytdehaag, F. & other authors (2013). PER.C6Hcells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine 31, 850–856.
35. Shiroki, K., Ishii, T., Aoki, T., Ota, Y., Yang, W. X., Komatsu, T., Ami, Y., Arita, M., Abe, S. & other authors (1997). Host range phenotype induced by mutations in the internal ribosomal entry site of poliovirus RNA. J Virol 71, 1–8.
36. Song, Y., Liu, Y., Ward, C. B., Mueller, S., Futcher, B., Skiena, S., Paul, A. V. & Wimmer, E. (2012). Identification of two functionally redundant RNA elements in the coding sequence of poliovirus using computer-generated design. Proc Natl Acad Sci U S A 109, 14301–14307.
37. SSI (2014). Description of VeroPol IPV Vaccine SSI. Copenhagen: Statens Serum Institute. http://www.ssi.dk/English/Vaccines/VeroPol.aspx
38. van der Werf, S., Bradley, J., Wimmer, E., Studier, F. W. & Dunn, J. J. (1986). Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A 83, 2330–2334.
39. Verdijk, P., Rots, N. Y., van Oijen, M. G., Weldon, W. C., Oberste, M. S., Okayasu, H., Sutter, R. W. & Bakker, W. A. (2014). Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 32, 4938–4944.
40. Westrop, G. D., Wareham, K. A., Evans, D. M., Dunn, G., Minor, P. D., Magrath, D. I., Taffs, F., Marsden, S., Skinner, M. A. & other authors (1989). Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63, 1338–1344.
41. WHO (2002). Recommendations for the production and control of poliomyelitis vaccine (inactivated). In Technical Report Series No. 910. Geneva: World Health Organization.
42. Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31, 3406–3415.